PMC10139808_01
The peripheral blood BCR-ABL1 transcript level throughout the disease course. IS: international scale.
CRIHEM2023-6673144.001.jpg
PMC10139808_01_CRIHEM2023-6673144.001.jpg
fig1
At eight months, the BCR::ABL1 transcript level was 2.9% (Figure 1) prompting the BCR::ABL1 KDM analysis by NGS of cDNA that revealed a D363G mutation (c.1088A > G, p.Asp363Gly, and NM_005157.6) present in 22% of expressed BCR::ABL1 transcripts. His TKI was switched to bosutinib 100 mg daily escalating to 500 mg daily which is continued and well tolerated with MMR maintained (Figure 1).